| 摘要 |
PURPOSE:To obtain the titled pharmaceutical containing a tumor necrosis factor (TNF). CONSTITUTION:A tumor vascular permeability accelerator obtained by containing a tumor necrosis factor (TNF), e.g. a recombinant type human tumor necrosis factor, produced in Escherichia coli by genetic engineering and having 155 amino acid residues, etc.; cellulicidal effect providing 50% survival rate after incubating 10,000 L-M cells derived from mice at 37 deg.C for 48hr is taken as 1 unit (U) for activity units of the TNF, as an active ingredient. The content of the TNF is 10,000-10,000,000U/day administered once or in divided portions. Distribution of a carcinostatic agent into cancerous tissues can be enhanced by administering this accelerator about 1hr before administering the carcinostatic agent.
|
